Co-Diagnostics (NASDAQ:CODX) specializes in designing and producing diagnostic solutions for diseases. Their operations focus on leveraging innovative technology to create diagnostics tests that are cost-effective, efficient, and reliable, addressing a myriad of infectious diseases globally. A significant part of their projects includes the development of tests for the detection of viruses, bacterial infections, and genetic mutations across various health sectors. Their objective is to improve public health through accessible diagnostic solutions, aiming to expand their reach in both developed and developing markets and adapt to emerging health challenges. Co-Diagnostics is committed to advancing healthcare standards and contributing to global disease control efforts.